NCT00287183 - 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Diabetic Nephropathy

Interventions

DRUG

PF-04494700 (TTP488)

60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication

OTHER

Placebo

Trial Locations (19)

T4N 6V7

Pfizer Investigational Site, Red Deer

V2A 5C8

Pfizer Investigational Site, Penticton

V6E 1M7

Pfizer Investigational Site, Vancouver

L7M 4Y1

Pfizer Investigational Site, Burlington

L1E 3C3

Pfizer Investigational Site, Courtice

L2A 1Z3

Pfizer Investigational Site, Fort Erie

L8M 1K7

Pfizer Investigational Site, Hamilton

N2G 1N9

Pfizer Investigational Site, Kitchener

N2H 5Z8

Pfizer Investigational Site, Kitchener

L9T 0H7

Pfizer Investigational Site, Millon

P1B 2H3

Pfizer Investigational Site, North Bay

L6H 3P1

Pfizer Investigational Site, Oakville

L2N 7H8

Pfizer Investigational Site, Saint Catherines

M1H 3G4

Pfizer Investigational Site, Scarborough Village

K7A 4W8

Pfizer Investigational Site, Smith Falls

L4J 8L7

Pfizer Investigational Site, Thornhill

M4N-3M5

Pfizer Investigational Site, Toronto

M4R 2G4

Pfizer Investigational Site, Toronto

S7K 0H6

Pfizer Investigational Site, Saskatoon